Issue Date | Title | Author(s) | Relation | scopus | WOS | Fulltext/Archive link |
1997 | Mig, the monokine induced by interferon-gamma, promotes tumor necrosis in vivo | Sgadari, C.; Farber, J. M.; Angiolillo, A. L.; Liao, F.; Teruya-Feldstein, J.; Burd, P. R.; Yao, L.; Gupta, G.; Kanegane, C.; Tosato, G. | Blood 89, 2635-2643 | | | |
1999 | MIP-3alpha induces human eosinophil migration and activation of the mitogen-activated protein kinases (p42/p44 MAPK) | Sullivan, S. K.; McGrath, D. A.; Liao, F.; Boehme, S. A.; Farber, J. M.; Bacon, K. B. | J Leukoc Biol 66, 674-682 | | | |
2010 | Pathway-selective suppression of chemokine receptor signaling in B cells by LPS through downregulation of PLC-beta2. | Shirakawa, A. K.; Liao, F.; Zhang, H. H.; Hedrick, M. N.; Singh, S. P.; Wu, D.; Farber, J. M. | Cellular & Molecular Immunology 7, 428-439 | | | |
1997 | STRL22 is a receptor for the CC chemokine MIP-3alpha | Liao, F.; Alderson, R.; Su, J.; Ullrich, S. J.; Kreider, B. L.; Farber, J. M. | Biochem Biophys Res Commun 236, 212-217 | | | |
1997 | STRL33, A novel chemokine receptor-like protein, functions as a fusion cofactor for both macrophage-tropic and T cell line-tropic HIV-1 | Liao, F.; Alkhatib, G.; Peden, K. W.; Sharma, G.; Berger, E. A.; Farber, J. M. | J Exp Med 185, 2015-2023 | | | |
1997 | Suppressive effects of recombinant human monokine induced by IFN-gamma (rHuMig) chemokine on the number of committed and primitive hemopoietic progenitors in liquid cultures of CD34+ human bone marrow cells | Schwartz, G. N.; Liao, F.; Gress, R. E.; Farber, J. M. | J Immunol 159, 895-904 | | | |
2002 | The CXC chemokine murine mig (CXCL9) is made by antigen presenting cells, targets lymphocytes including activated B cells, and supports antibody responses to a bacterial pathogen in vivo | Park, M. K.; Amichay, D.; Love, P.; Wick, E.; Liao, F.; Grinberg, A.; Rabin, R. L.; Zhang, H. W.; Gebeyehu, S.; Wright, T.; Iwasaki, A.; Weng, Y.; DeMartino, J.; Elkins, K.; Farber, J. M. | J Immunol 169, 1433-1443 | | | |
1998 | Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis | Coughlin, C. M.; Salhany, K. E.; Gee, M. S.; LaTemple, D. C.; Kotenko, S.; Ma, X.; Gri, G.; Wysocka, M.; Kim, J. E.; Liu, L.; Liao, F.; Farber, J. M.; Pestka, S.; Trinchieri, G.; Lee, W. M. | Immunity 9, 25-34 | | | |